USA Insider Trading Pulse — September 10, 2026

10% owner Cascade Investment made a massive $55.4M open-market purchase at ~$221.82, increasing its stake by 249,866 shares. This is a high-conviction signal from a sophisticated, long-term investor in a stable, cash-flow-generative business.

The Executive Chair and Chief Growth Officer collectively bought $2.39M worth of shares at ~$11.78-$12.09. This is a powerful vote of confidence from top leadership in a clinical-stage biotech, suggesting they see significant upside ahead of potential catalysts.

CEO Prashant Kohli purchased $214K worth of stock at $2.14, increasing his stake by over 500%. This is a strong insider buy at a low price point, signaling management's belief the company is undervalued.

The CFO bought $5.22K worth of stock at $1.00, a small but symbolically positive purchase at a very low share price, indicating insider confidence in the company's turnaround prospects.

The CEO, CAO, and SVP of HR all sold shares at $122.62 in a coordinated fashion, totaling ~$462K. This is a bearish signal from multiple C-suite insiders, suggesting they believe the stock is fairly valued or overvalued at current levels.

The CEO and CRO sold a combined $2.62M in shares at ~$86.53-$86.94 under 10b5-1 plans. While pre-planned, the size and timing of these sales from top revenue-generating executives is a cautionary signal.

The Chairman and CEO sold $1.11M worth of stock at $222.44 after exercising options at $146.34. This is a classic profit-taking move, but the sheer size of the sale warrants attention as a potential top signal.

Director Marc Andreessen sold $2.48M of Class A Common Stock at $181.14 under a 10b5-1 plan. A high-profile insider reducing a large position, even under a plan, can dampen sentiment.

The Chief Investment Officer sold $101K worth of stock at $16.82 under a 10b5-1 plan. While not massive, a CIO selling shares can be interpreted as a lack of confidence in the company's near-term valuation.

The EVP & CFO sold $90.4K worth of shares at $29.91 after exercising options. This is a bearish signal from a key financial officer in a volatile shipping sector.

A 10% owner, HRT Financial LP, sold 60% of its stake (40,841 shares) at $0.71. This is a strong vote of no confidence from a significant shareholder.

The CEO, CAO, and SVP of HR all sold shares on the same day at the same price ($122.62). This coordinated selling by multiple C-suite executives is a major red flag for corporate governance and future performance.

The CEO and CRO sold over $2.6M in a single day. While under 10b5-1 plans, the magnitude of sales from the top revenue and executive leadership suggests they may be locking in gains ahead of a potential slowdown.

HRT Financial LP sold 40,841 shares, reducing its stake by ~60%. This is a strong signal of distress or lack of confidence from a sophisticated institutional investor.

Director Marc Andreessen sold $2.48M. While under a 10b5-1 plan, the sale of a large block by a high-profile venture capitalist could signal a peak in crypto-related equity valuations.

The Chairman and CEO sold $1.11M worth of stock, a significant personal liquidity event. While not a sale from a distressed position, it removes a large block of insider ownership and can be a top signal.

The EVP & CFO sold shares after exercising options. Insider selling by a CFO, especially in a cyclical industry, often precedes weaker financial results.

The Chief Investment Officer sold 6,000 shares. An insider responsible for capital allocation selling shares can be interpreted as a lack of confidence in the company's investment strategy or valuation.

14 directors and officers received stock awards. While this is standard compensation, the sheer volume of awards (over 1,000 shares total) could lead to future dilution and selling pressure.

Six directors were each awarded 545,833 shares of common stock. This is an enormous grant that will massively dilute existing shareholders and raises questions about corporate governance.

A 10% owner's massive open-market purchase is a powerful signal of deep value. RSG is a defensive, cash-flow-generative business, and this insider activity suggests the stock is undervalued.

The Executive Chair and CGO bought $2.39M worth of stock. This is a high-conviction bet by top insiders in a clinical-stage biotech, likely anticipating positive trial data or a partnership.

The CEO's $214K purchase at $2.14 is a strong signal of undervaluation. With a market cap likely under $50M, this could be a high-risk, high-reward turnaround play.

A CFO buying shares at $1.00 is a classic value signal. The company is a micro-cap, but insider buying at such a low price point suggests a potential catalyst or asset value unlock.

10% owner Eric L. Oliver bought 7,134 units at ~$11.29. This is a consistent buyer adding to a position in a royalty trust, which offers a high dividend yield and is a play on energy prices.

A 10% owner bought 10,000 shares at $0.40. This is a small but symbolic purchase in a micro-cap, suggesting the insider sees value at these depressed levels.

The CEO bought 3,100 shares at $3.93. This is a small but positive signal from the CEO of a small-cap biotech, indicating confidence in the company's pipeline.

While not open-market buys, the award of 333,332 shares and warrants to the CEO and directors at $3.00 aligns their interests with shareholders and suggests a belief in the company's future value.

The data shows a clear divide: large-cap tech insiders (TWST, FROG, RMD, COIN) are selling, while value-oriented (RSG) and micro-cap (CYBN, GRCE, BRN) insiders are buying. This suggests a rotation from growth to value and a preference for smaller, catalyst-driven names.

The majority of large insider sales (TWST, FROG, RMD, COIN) were executed under Rule 10b5-1 plans. While pre-planned, the concentration of these sales in the tech sector signals that executives are systematically de-risking their personal portfolios.

A significant number of micro-cap companies (CYBN, GRCE, BRN, TOFB, YDB) saw insider buying. This is a classic contrarian signal, suggesting that insiders at these beaten-down names see a disconnect between price and intrinsic value.

Multiple companies (Aramark, Latch, Sphere 3D) issued large stock awards to directors. While standard practice, the sheer size of the Latch awards (545,833 shares per director) highlights a significant dilution risk for shareholders.

The 10% owner of Cross Timbers Royalty Trust (CRT) is consistently buying units. This signals a bullish view on energy prices and the trust's ability to generate cash flow, a theme that contrasts with the selling in tech.

Both Cybin (psychedelics) and Grace Therapeutics (specialty pharma) saw significant insider buying. This suggests a pocket of optimism within the healthcare sector, likely tied to upcoming clinical data or product launches.

Watch for further insider selling or a change in guidance. The coordinated C-suite selling at $122.62 is a major red flag. Next earnings call will be critical.

Monitor for any insider buying to offset the CEO/CRO selling. The $2.6M in sales is a significant overhang. Watch for Q3 earnings to see if revenue growth justifies the valuation.

Watch for any additional purchases by Cascade Investment. A continued buying spree would be a massive bullish signal for the waste management sector.

The $2.39M insider purchase is a strong catalyst signal. Watch for upcoming clinical trial results or partnership announcements. The next few months are critical.

The massive director stock awards (545,833 shares each) are a red flag for dilution. Watch for any insider selling after these awards vest. The company's next shareholder meeting will be key.

The 10% owner sold 60% of its stake. Watch for further selling or a potential going-private transaction. The stock is under significant pressure.

The CEO's $1.1M sale is a potential top signal. Watch for any follow-on sales by other insiders. The company's next earnings report will be crucial to see if growth is slowing.

Director Marc Andreessen's $2.48M sale is a high-profile event. Watch for any correlation with Bitcoin price movements and further insider selling. The next crypto regulatory update will be a catalyst.